On January 13, 10 times of “bull stocks” Andon Health Co.Ltd(002432) (002432) rose again, and 26 trading boards have been harvested in the past two months.
On the morning of 14, Andon Health Co.Ltd(002432) announced that the U.S. subsidiary and ACC signed a purchase contract on January 13, 2022 local time to sell ihealth kit products to them. The total amount of contract price tax is $1.275 billion, about 8.1 billion yuan, which has exceeded 50% of the company’s audited main business income in 2020.
On January 13, the company announced that the grant registration of the stock option incentive plan in 2021 was completed, and a total of 7.37 million shares were granted to 353 core backbone with an exercise price of 6.49 yuan / share. The incentive object can exercise and buy in four phases when the company’s performance and personal performance appraisal meet the standards within four years after 16 months. If the employee can exercise at the latest share price of 68.44 yuan / share at that time, It will realize more than 9 times of revenue.
It is worth mentioning that although the option has not yet been cashed, the Andon Health Co.Ltd(002432) previous incentive plan has entered the exercise period. Measured at the current price, the per capita floating profit has exceeded 900000 yuan.
As a well deserved “trading king” in the covid-19 detection reagent sector, Andon Health Co.Ltd(002432) has issued change announcements since November, which have also become the focus of the regulatory authorities. So far, 9 stock price change announcements have been issued, and 4 attention letters and 1 supervision letter have been received.
stock option yield or more than 9 times
Looking back at the stock price trend of Andon Health Co.Ltd(002432) , the launch of this stock option incentive plan coincides with the time. On October 28, 2021, the company issued the equity incentive draft for the first time, and the closing price on that day was only 5.86 yuan / share, which was still at the bottom. According to the pricing principle, the higher of the average price of the previous trading day and 20 trading days before the announcement of the draft is the exercise price, specifically 6.49 yuan / share.
Surprisingly, after a series of deliberation procedures such as the board of directors and the general meeting of shareholders and the legal grant registration process, Andon Health Co.Ltd(002432) soared, with the latest closing of 68.44 yuan / share, which has reached 10 times the exercise price. According to this calculation, the return on stock options will reach 954.5%. However, the incentive object can enter the exercise period only after 16 months. During this period, the stock price trend of the company has great uncertainty, and the actual rate of return has yet to be verified.
Although the option has not been cashed yet, the previous incentive plan has entered the first exercise period since the end of October 2021, and employees can choose to be safe. According to the data, the exercise price of the previous option was 11.53 yuan / share, a total of 187 incentive objects met the exercise conditions, and the number of stock options available was 3.047 million shares. If you choose to exercise at the current price, the cumulative floating profit has reached 170 million yuan and the per capita income has reached 927000 yuan.
At the level of performance appraisal, Andon Health Co.Ltd(002432) has been revised once. The previous assessment objective was to take the operating income in 2019 as the base, and the revenue growth rates from 2021 to 2024 were no less than 20%, 40%, 70% and 80% respectively; In the first three quarters of 2021, the company achieved a revenue of 790 million yuan, which has completed 93.27% of the annual assessment indicators. It seems that it is easy to meet the standard, which has been concerned by the regulatory authorities; Subsequently, the company revised the indicators, extended the assessment year back one year, and changed it to take the operating revenue of 2019 as the base. The revenue growth rates from 2022 to 2024 are no less than 40%, 70%, 80% and 90% respectively, specifically no less than 988 million yuan, 1.2 billion yuan, 1.27 billion yuan and 1.34 billion yuan.
From the perspective of the composition of incentive objects, the proportion of managers, directors and above has exceeded 40%. Among them, Wang Yong and Cong Ming, the company’s directors and deputy general managers, were granted 75000 shares, and sun Zhe, the chief financial officer and Wu Tong, the Secretary of the board of directors, were granted 25000 shares, accounting for 2.72% in total. In the previous incentive plan, Wang Yong and Cong Ming were granted 300000 shares, of which 75000 shares can be exercised, with a per capita floating profit of about 4.27 million yuan; Sun Zhe and Wu Tong were granted 100000 shares, 25000 of which have met the exercise conditions, with a floating profit of about 1.42 million yuan.
covid-19 test reagent business messages are frequent
in the covid-19 detection reagent sector, Andon Health Co.Ltd(002432) is not the largest business, but in terms of growth, it is most sought after by the secondary market. On November 15, 2021, Andon Health Co.Ltd(002432) opened the soaring mode, and there was little correction, becoming a 10x bull stock at one fell swoop.
Back on November 8, 2021, the company disclosed that its subsidiary ihealth labs Inc. The New Coronavirus antigen self testing OTC kit is used to obtain US emergency use authorization (EUA). It can be sold in the United States and the US EUA countries / regions during the public health emergency period in the US, and it is expected that the relevant sales revenue may be brought in the future. According to the introduction, the purchase of the kit mentioned above does not require prescription, and the US electricity suppliers, drugstores and commercial super channels are all sold. Subsequently, the company frequently interacted with investors on the interactive easy platform on the aforementioned business, and revealed that the kit has started mass production and sold well in local spot, the sales price on the official website is $6.99 (1 person), belongs to the product category intensively purchased by the U.S. federal government, the current monthly production capacity is 100 million people, and is expected to increase to 200 million people per month in early 2022.
Since then, Andon Health Co.Ltd(002432) has released the R & D and sales progress of the self-test kit through various channels such as interactive easy platform and announcement, including that as of December 1, 2021, the company’s covid-19 test reagent ranked first in the sales of Amazon’s U.S. website, and it is believed that the company’s antigen test products can detect the Omicron variant strain. On January 7, the company announced that it had received the performance test report of the Radx project of the National Institutes of health on the Omicron variant virus of the company’s covid-19 antigen home self-test, which showed that the kit detected 100% of the Omicron active virus samples with a maximum CT value of 21.59.
In response to the news successively released by the above Andon Health Co.Ltd(002432) , the exchange has issued three attention letters for tracking, and issued a supervision letter on December 14.
It is worth mentioning that Andon Health Co.Ltd(002432) which has been noisy for a long time on the news surface has ushered in the landing of large orders. As of January 12, the cumulative amount of orders and contracts between its U.S. subsidiary and the Department of health of New York state reached RMB 1.18 billion, and the contract amount signed with the Executive Office of the Federal Department of health and human services of Massachusetts was about RMB 940 million. The cumulative amount of the above orders reached RMB 2.1 billion, which exceeded the total operating revenue of the company in 2020.
In the face of the continuous galloping stock price, Andon Health Co.Ltd(002432) has repeatedly made risk tips, indicating that the demand for antigen home self-test kit products is directly related to the development of the epidemic in the United States. Virus variation, vaccination and the launch of covid-19 drugs will have an impact on the development of the epidemic. There is strong uncertainty in the demand and sales of the company’s related products in the future.
